GlaxoSmithKline
Flu mRNA (Formulation B1)
Influenza, Human
Countdown
25days
Phase 2 readout · Jul 31, 2026
What's at stake
Phase 2 trial results for Flu mRNA (Formulation B1) in Influenza, Human are due Jul 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07204964: Phase 2 trial, sponsor GlaxoSmithKline, drug Flu mRNA (Formulation B1). Primary completion date 2026-07-31 (estimated).”